Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ACC In Brief

This article was originally published in The Gray Sheet

Executive Summary

TAXUS II: Anti-restenotic effects of paclitaxel are maintained beyond the cessation of clopidogrel therapy at six months post-implant, according to twelve-month data from Boston Scientific's trial of the Taxus paclitaxel-eluting stent, presented March 27 by Antonio Columbo, MD, Centro Cuore Columbus, Milan. Target lesion revascularization rates were 4.7% and 3.8% in the slow drug-release and moderate drug-release groups, respectively at 12 months, compared with 14.4% in the control group. One-year follow-up results represent a slight increase in each group over the six-month TLR rates presented in September at the annual TCT meeting in Washington, D.C. (1"The Gray Sheet" Sept. 30, 2002, p. 5)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT018137

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel